ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis

NASDAQ:ASTH • US03763A2078

19.45 USD
+0.23 (+1.2%)
At close: Feb 18, 2026
19.45 USD
0 (0%)
After Hours: 2/18/2026, 8:14:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ASTH gets a fundamental rating of 4 out of 10. We evaluated ASTH against 102 industry peers in the Health Care Providers & Services industry. While ASTH is still in line with the averages on profitability rating, there are concerns on its financial health. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year ASTH was profitable.
  • In the past year ASTH had a positive cash flow from operations.
  • In the past 5 years ASTH has always been profitable.
  • In the past 5 years ASTH always reported a positive cash flow from operatings.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • ASTH has a Return On Assets (0.43%) which is in line with its industry peers.
  • ASTH has a Return On Equity of 1.23%. This is comparable to the rest of the industry: ASTH outperforms 52.94% of its industry peers.
  • ASTH's Return On Invested Capital of 2.95% is in line compared to the rest of the industry. ASTH outperforms 47.06% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ASTH is in line with the industry average of 8.98%.
  • The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROIC 2.95%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.33%, ASTH is in line with its industry, outperforming 47.06% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ASTH has declined.
  • ASTH has a Operating Margin of 2.59%. This is comparable to the rest of the industry: ASTH outperforms 53.92% of its industry peers.
  • ASTH's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 73.53% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ASTH is destroying value.
  • ASTH has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.13 indicates that ASTH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.13, ASTH perfoms like the industry average, outperforming 51.96% of the companies in the same industry.
  • ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
  • ASTH has a Debt to FCF ratio of 10.83. This is comparable to the rest of the industry: ASTH outperforms 43.14% of its industry peers.
  • ASTH has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
  • ASTH's Debt to Equity ratio of 1.29 is on the low side compared to the rest of the industry. ASTH is outperformed by 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Altman-Z 2.13
ROIC/WACC0.35
WACC8.33%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Current ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 52.94% of its industry peers.
  • A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Quick ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 58.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The earnings per share for ASTH have decreased strongly by -85.38% in the last year.
  • Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.19% on average per year.
  • Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 68.17%.
  • The Revenue has been growing by 38.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.87% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ASTH will show a quite strong growth in Revenue. The Revenue will grow by 18.29% on average per year.
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 102.37, the valuation of ASTH can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
  • When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (27.27), we can say ASTH is valued expensively.
  • ASTH is valuated correctly with a Price/Forward Earnings ratio of 15.25.
  • 79.41% of the companies in the same industry are more expensive than ASTH, based on the Price/Forward Earnings ratio.
  • ASTH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.16, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 102.37
Fwd PE 15.25
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • ASTH's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 83.33% of the companies in the same industry are more expensive than ASTH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 10.06
EV/EBITDA 13.86
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ASTH's earnings are expected to grow with 29.02% in the coming years.
PEG (NY)N/A
PEG (5Y)5.33
EPS Next 2Y19.69%
EPS Next 3Y29.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ASTH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRANA HEALTH INC

NASDAQ:ASTH (2/18/2026, 8:14:53 PM)

After market: 19.45 0 (0%)

19.45

+0.23 (+1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners55.03%
Inst Owner ChangeN/A
Ins Owners9.86%
Ins Owner Change0.95%
Market Cap975.61M
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts84.71
Price Target37.17 (91.11%)
Short Float %6.57%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.25%
PT rev (3m)-19.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-75.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 102.37
Fwd PE 15.25
P/S 0.34
P/FCF 10.06
P/OCF 9.16
P/B 1.26
P/tB N/A
EV/EBITDA 13.86
EPS(TTM)0.19
EY0.98%
EPS(NY)1.27
Fwd EY6.56%
FCF(TTM)1.93
FCFY9.94%
OCF(TTM)2.12
OCFY10.92%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)N/A
PEG (5Y)5.33
Graham Number8.13
Profitability
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROCE 4.68%
ROIC 2.95%
ROICexc 4.15%
ROICexgc N/A
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
FCFM 3.35%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Debt/EBITDA 8.9
Cap/Depr 25.55%
Cap/Sales 0.33%
Interest Coverage 2.01
Cash Conversion 94.59%
Profit Quality 1016.69%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.13
F-Score3
WACC8.33%
ROIC/WACC0.35
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.68%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A

ASTRANA HEALTH INC / ASTH FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 102.37 and the Price/Book (PB) ratio is 1.26.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.